Gilead Sciences (Nasdaq: GILD) has agreed to buy immunotherapy cancer biotech Arcellx (Nasdaq: ACLX) in a deal worth $7.8 billion, the companies announced Monday.
Why it matters: The transaction deepens Gilead's bet on cancer immunotherapy and its existing Arcellx partnership.
